Starpharma Holdings Ltd has released a press release.
Positive DEP irinotecan clinical results presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- App 4E/Annual Report to shareholders
- SPL to receive $6.5M from Mundipharma and VivaGel BV rights
- Partnered Program Update
- Trading Halt
- Pause in Trading
Later from Starpharma
- VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
- DEP irinotecan combination data presentation
- DEP irinotecan clinical data presented at AACR meeting
- Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
- Starpharma receives $7.2 million R&D Tax Incentive refund
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma